聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎疗效观察

目的:探讨慢性丙型肝炎(CHC)治疗的有效途径。方法:将116例CHC患者随机分组,在利巴韦林依给药基础上,对照组(56例)给予普通干扰素α-2b(INFα)3MU/次,3次/周,肌肉注射;观察组(60例)给予聚乙二醇干扰素α-2a(PEG-INFα)180μg,1次/周,皮下注射。疗程48周,停药后观察24周。结果:两组治疗结束和随访24周的ALT复常率分别为46.4%、86.7%和32.1%、70.0%,HCV-RNA阴转率,治疗结束时应答(ETVR)为32.1%和70.0%,持续病毒学应答(SVR)为46.4%和93.3%(P<0.01)。结论:PEG-INFα联合利巴韦林是治疗CHC的有效方法。

Efficacy of pegylated interferon combing with ribavirin on chronic hepatitis C

Objective: To explore an effective treatment for chronic hepatitis C(CHC).Methods:A total of 116 CHC cases were randomized divided into treatment group and control group.Based on ribavirin,the control group(n=56) was given interferon α-2b(INFα) 3 MU / time,3 times / week,intramuscularly;the observation group(n=60 cases) was given peginterferon α-2a(PEG-INFα) 180 μg,1 times / week,subcutaneously.Treatment course was 48 weeks for both groups,after withdrawal of drugs,follow-up of 24 weeks were conducted.Results:Follow up showed that 46.4% and 86.7% patients in the control and observation group normal ALT level when the treatment course ended,these data decreased to be 32.1% and 70.0% respectively 24 weeks after withdrawal of drugs.When the treatment course ended,ETVR was 32.1% and 70.0% in the control group and observation group;SVR was 46.4% and 93.3% separately(P both <0.01).Conclusions:PEG-INFα ribavirin is an effective treatment for CHC.